Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13337684 | 0.97 | CYP3A4 (0.44) | MEN1KMT2ACYP3A4LTA4H | |
| SCHEMBL13337665 | 0.93 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL13337650 | 0.79 | NPSR1 (0.48) | MEN1KMT2A | |
| SCHEMBL28254358 | 0.75 | MEN1 (0.62) | MEN1KMT2ACYP3A4 | |
| SCHEMBL30643928 | 0.73 | CYP3A4 (0.48) | CYP3A4 | |
| SCHEMBL8717832 | 0.73 | KIF11 (0.44) | LTA4H | |
| SCHEMBL11889545 | 0.72 | CYP3A4 (0.52) | MEN1KMT2ACYP3A4LTA4H | |
| SCHEMBL8945869 | 0.71 | ALDH1A1 (0.42) | — | |
| SCHEMBL18375740 | 0.71 | KCNN4 (0.46) | MEN1KMT2ACYP3A4 | |
| SCHEMBL13337689 | 0.71 | TSHR (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709465-B2 | Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709465-B2 | Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090004293-A1 | Phosphorous Containing Compounds Including Triphenylmethylphosphonate Esters for the Treatment of Melanoma and Other Cancers | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-01 | — | — | US | disclosed |
| US-20090004293-A1 | Phosphorous Containing Compounds Including Triphenylmethylphosphonate Esters for the Treatment of Melanoma and Other Cancers | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004293-A1 | Phosphorous Containing Compounds Including Triphenylmethylphosphonate Esters for the Treatment of Melanoma and Other Cancers | PHOSPHO1, MCL1, MTMR1 | MEN1 482/4885KMT2A 1863/4885CYP3A4 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.